Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer
Publication year
2013Source
Expert Review of Anticancer Therapy, 13, 11, (2013), pp. 1257-1268ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Urology
Journal title
Expert Review of Anticancer Therapy
Volume
vol. 13
Issue
iss. 11
Page start
p. 1257
Page end
p. 1268
Subject
NCEBP 1: Molecular epidemiology; ONCOL 3: Translational research; ONCOL 4: Quality of Care; ONCOL 5: Aetiology, screening and detection; ONCOL 5: Aetiology, screening and detectionAbstract
Non-muscle-invasive bladder cancer is a highly prevalent disease and recurrences, after initial therapy, are common. Consequently, the healthcare costs for non-muscle-invasive bladder cancer are high. Despite a primary adequate response to adjuvant intravesical treatment, many patients suffer from recurrences, and some even from progression. To date, cystectomy remains the only option for those non-responding patients with high risk of recurrence and progression. Mainly because outcome after progression, in this group, is poor. Therefore, new intravesical therapies are needed. Moreover, new accurate and individual parameters, to distinguish responder from non-responders, will provide additional benefit in clinical decision-making. In this review, current diagnostics and therapies will be discussed. In addition, we will elucidate developing therapies in non-muscle-invasive bladder cancer.
This item appears in the following Collection(s)
- Academic publications [203587]
- Faculty of Medical Sciences [80231]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.